太龙药业：终止第四期员工持股计划并注销回购股份，拟减少注册资本
2026年5月1日，河南太龙药业股份有限公司（600222.SH）发布公告，宣布终止实施公司第四期员工持股计划，同时将此前为员工持股计划或股权激励回购的股份变更用途，拟予以注销并减少公司注册资本。
主要内容梳理：
- 公司原计划以自有资金回购股份用于实施员工持股计划或股权激励，回购价格不高于7元/股，回购资金总额不低于4,000万元且不超过8,000万元。
- 截至2023年7月13日，公司通过集中竞价方式共回购股份14,523,100股，占总股本的2.53%，回购均价为5.49元/股，使用资金总额为79,724,005.75元。
- 2023年10月-11月，公司已就第四期员工持股计划相关议案履行了董事会、监事会、职工代表大会及股东大会等审议流程，且员工持股计划股票来源即为上述已回购股份，受让价格为5.49元/股。
- 截至本公告披露日，该员工持股计划尚未进行股份非交易过户，员工也未签署认购协议或实际缴款。
- 因市场融资环境变化及方案实施期限等多种因素影响，公司经充分征求员工意见后，决定终止该期员工持股计划，并将已回购股份全部用于注销注册资本。
对公司股本结构及影响：
- 本次拟注销14,523,100股，占总股本2.53%。注销完成后，公司总股本将由573,886,283股减少至559,363,183股，注册资本同步减少。
- 本次决策有利于提升每股收益、提升股东回报，并不会影响公司债务履约及持续经营能力，也不会导致公司控制权发生变化。
- 注销完成后，公司股权结构仍符合上市公司规范要求，不影响公司上市地位。
决策程序与后续安排：
- 该事项已于2026年4月30日经董事会薪酬与考核委员会及董事会审议通过。因涉及关联董事，李景亮先生已回避表决。
- 相关议案尚需提交公司股东大会审议，董事会将授权经营管理层办理后续股份注销及工商变更等事项。
对股东及股价的潜在影响（值得关注的敏感点）：
- 股份注销将直接减少公司总股本，理论上将提升每股收益，有利于现有股东利益。
- 终止员工持股计划，释放出原本锁定的股份用于注销，显示公司对自身长期价值有信心，并可能被市场解读为管理层看好公司未来发展。
- 若市场对注销行为反应积极，短期内有助于提振公司股价。
- 但终止员工持股计划亦显示公司融资或激励计划受市场环境影响，需关注公司后续治理及激励机制调整。
风险提示：
- 公告所述事项尚需股东大会审议通过，存在一定不确定性。
- 股份注销和员工持股计划终止不会对公司持续经营和控制权产生重大影响，但需关注市场对此解读及后续实际执行情况。
免责声明：本资讯仅供参考，内容基于公告原文梳理，不构成任何投资建议。投资者据此操作，风险自担。
Tailong Pharmaceutical: Termination of the Fourth Employee Stock Ownership Plan and Cancellation of Repurchased Shares, Plan to Reduce Registered Capital
On May 1, 2026, Henan Tailong Pharmaceutical Co., Ltd. (600222.SH) announced the termination of its fourth employee stock ownership plan (ESOP). The company will change the use of previously repurchased shares (originally for ESOP or equity incentives) to cancellation, thus reducing its registered capital.
Key Points:
- The company initially planned to use its own funds to repurchase shares for ESOP or equity incentives, with a repurchase price not exceeding RMB 7/share and a total amount between RMB 40 million and 80 million.
- As of July 13, 2023, a total of 14,523,100 shares had been repurchased via centralized bidding, accounting for 2.53% of total share capital, at an average price of RMB 5.49/share, using RMB 79,724,005.75 in total funds.
- From October to November 2023, the ESOP proposal went through various meetings (board, supervisory board, employee representative meeting, and EGM), with the repurchased shares as the source, to be transferred at RMB 5.49/share.
- As of the date of this announcement, no shares have been transferred to employees, no subscription agreements signed, and no employee payments received.
- Due to changes in the financing environment and time constraints, and after consulting ESOP participants, the company decided to terminate the plan and use all repurchased shares for capital reduction.
Impact on Share Capital Structure:
- The company will cancel 14,523,100 shares (2.53% of total), reducing total share capital from 573,886,283 to 559,363,183 shares and registered capital accordingly.
- This move is beneficial for increasing EPS and shareholder returns, does not affect debt servicing or ongoing operations, and will not change the company’s control structure.
- After cancellation, the company’s equity structure remains compliant with listing standards, and the listing status is unchanged.
Decision Process and Next Steps:
- The matter was approved by the Remuneration and Appraisal Committee and the Board on April 30, 2026. Related director Mr. Li Jingliang abstained.
- The proposal still requires shareholder approval, after which management is authorized to handle share cancellation and business registration changes.
Potentially Price-Sensitive Points for Investors:
- Share cancellation will reduce total share capital and theoretically boost earnings per share, beneficial to current shareholders.
- Terminating the ESOP frees up shares for cancellation, signaling management’s confidence in long-term company value, which may be viewed positively by the market.
- If the market responds favorably, the share price may receive a short-term boost.
- However, the ESOP termination also suggests that company incentive or financing plans are affected by market conditions. Investors should watch for subsequent governance and incentive plan adjustments.
Risk Reminder:
- The plan is subject to shareholder meeting approval and may change.
- The cancellation and ESOP termination do not affect company operations or control, but market reactions and actual execution should be monitored.
Disclaimer: This report is for informational purposes only, based on official disclosures, and does not constitute investment advice. Investors act at their own risk.
View 太龙药业 Historical chart here
